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Background: AMP-activated protein kinase (AMPK) has recently been considered as a potential target for cancer
therapy. However, the expression status of various subunits of the heterotrimeric AMPK in human cancers is rarely
reported. We decided to determine their expressions in ovarian carcinomas and their relationships with the disease.
Methods: Expressions and locations of the AMPK-α1, -α2, -β1, -β2, -γ1 and -γ2 were detected by quantitative PCR
(Q-PCR) and immunohistochemical staining (IHC). Their expression levels in ovarian tumors were compared with
normal controls and also correlated with clinicopathological parameters.
Results: Except AMPK-α1, expressions of the other five AMPK subunits are significantly higher in ovarian carcinomas as
determined by Q-PCR. Although IHC detection of AMPK-γ1 and -γ2 were not successful, over-expressions of AMPK-α2, -β1,
and -β2 were further confirmed by IHC. Over-expressions of various AMPK subunits occurred independently and were
mainly detected in the cytoplasm. Interestingly, AMPK-α2 and -β1 were also detected in the nucleus and cell membrane,
respectively. Clinical correlation analyses indicate that expressions of different AMPK subunits are associated with different
subtypes of carcinoma. High expression of AMPK-α2 is significantly associated with endometrioid carcinomas. On the
other hand, high expressions of AMPK-β and -γ subunits are associated with mucinous and serous carcinomas,
respectively. Furthermore, high expressions of AMPK-β1 and -γ2 are also associated with early and late stages of disease,
respectively. Finally, patients with high expression of AMPK-α2 had better prognosis.
Conclusions: Aberrant expressions of AMPK subunits may play important roles in ovarian carcinogenesis. Each AMPK
subunit may have its own function other than just a component of the AMPK molecule. Correlations with clinical
parameters suggest that expressions of AMPK subunits have different clinical implications in ovarian cancer development.
Keywords: AMPK, AMPK subunits, Differential gene expression, Ovarian carcinomaBackground
AMP-activated protein kinase (AMPK) is a well-known
cellular energy-balancing sensor [1,2], an important cell
proliferation inhibitor [3], and a potential target for can-
cer treatment [4]. Pharmacological activation of AMPK
using AICAR or metformin can inhibit the growth or
induce apoptosis of a wide spectrum of cancer cells,
including cervical [5] and ovarian [6-8] cancers, through
modulation of p53, p27, or p21 activities and cellular
activities such as cell polarity and mitosis [2,3,9]* Correspondence: vwsliu@hku.hk; hysngan@hku.hk
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reproduction in any medium, provided the orAMPK is a heterotrimer composed of a catalytic sub-
unit (α) and two regulatory subunits (β and γ) [2]. Each
subunit has different isoforms, namely, α1, α2, β1, β2,
γ1, γ2, and γ3 encoded by distinct genes, which enable
the yielding of 12 possible heterotrimeric combinations.
The functional aspects of AMPK have been extensively
studied recently and reviewed in metabolic diseases and
human cancers [2,3]. In contrast, the expression levels of
the individual subunits of AMPK and their clinical sig-
nificance in human cancers are rarely investigated. It
would be intriguing to delineate the expression status of
all AMPK subunits in ovarian cancer and their potential
correlations with clinical presentations.
Therefore, in the present study, quantitative PCR
(Q-PCR) and immunohistochemical (IHC) staining were
used to determine the expressions and cellular locationshis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ovarian tissues. The expressions of AMPK subunits in
ovarian cancer were then correlated with the clinical data.
Methods
Clinical samples
To recruit tissues for research study, patient’s consent
was obtained before surgery at Queen Mary Hospital,
Hong Kong. The use of the clinical specimens was
approved by the local Institutional Review Board.
Tumors containing more than 70% tumor cells were
only used in the present study. A total of 76 tumor sam-
ples surgically resected from primary ovarian cancer
patients and 53 normal ovary samples from benign dis-
eases (including 5 borderline cases) were randomly
selected for this study. The histological subtypes and dis-
ease stages of the tumors were classified according to
International Federation of Gynecology and Obstetrics
(FIGO) criteria. Clinical data of patients were retrieved
from the records kept at the Department of Obstetrics &
Gynecology, Queen Mary Hospital, Hong Kong.
RNA extraction and quantitative PCR analysis
Total RNA from the ovarian tissues was prepared using the
TRIzol reagent (Invitrogen). Quality and quantity of RNA
were determined by agarose electrophoresis and spectro-
photometry, respectively. The cDNA was then prepared
using the Taqman reverse transcription kit according to the
manufacturer’s instructions (Applied Biosystems, Foster
City, CA). The gene expression assay kits were also pur-
chased from Applied Biosystems. The primers and probes
used to detect and quantify the expressions of AMPK subu-
nits were AMPK-α1 (Assay ID: Hs00178893_m1); AMPK-
α2 (Hs00178903_m1); AMPK-β1 (Hs00272166_m1); AMPK
-β2 (Hs00271294_m1); AMPK-γ1 (Hs00176952_m1); and
AMPK-γ2 (Hs00211903_m1).
The real-time quantitative PCR (Q-PCR) was performed
in an ABI 7500 system (Applied Biosystems). The relative
expression level of each gene was normalized against the
endogenous β-actin (Product no: 4326315E) control. The
GAPDH (Assay ID: Hs99999905_m1) control was also
used to further verify the relative expression level of each
gene. The relative quantity of the RNA expression was cal-
culated using the comparative CT method with the 7500
System SDS software [10].
Immunohistochemical staining
Immunohistochemical (IHC) staining for the six AMPK
subunits was performed separately on an ovarian cancer
tissue array (OVC1021) (Pantomics Inc, San Francisco,
CA). The tissue array contains 97 cancer cases and 5 nor-
mal/benign cases. The antibodies against the six AMPK
subunits were all purchased from Cell Signaling Technol-
ogy, Inc., USA. They were anti-AMPK-α1 (Cat. no.: 2795);anti-AMPK-α2 (2757); anti-AMPK-β1 (4182); anti-AMPK-
β2 (4148); anti-AMPK-γ1 (4187); and anti-AMPK-γ2
(2536). In addition, the anti-phospho-AMPK-α (2535) was
also use to detect the phospho-AMPK-α. The details of the
IHC staining procedures have been published elsewhere
[11,12]. The percentages of positively stained cells in
tumors and normal epithelia were assessed. The propor-
tions of positive cells were ranged from 10 to 100%, while
the intensity of staining was scored as 0 (negative), 1 (very
weak), 2 (weak), 3 (moderate), 4 (intense), and 5 (very in-
tense) in the most strongly stained tumor area. The immu-
noreactivity score for each case was taken as percentage of
positive cells multiplied by the intensity of staining.
Confocal microscopy
The cellular locations of AMPK-α2, -β1 and -γ2 were
examined in the ovarian cancer cells, A2780CP and
SKOV3. The pCMV6–AMPK-α2–GFP, pCMV6–AMPK-
β1–GFP and pCMV6–AMPK-γ2–GFP tagged plasmids
(OriGene Technologies) were used. The analytical pro-
cedure has already been reported in a previous study
[12]. The fluorescence signals were captured through
confocal microscopy.
Statistical analysis
Statistical analysis was performed using Chi-squared test to
evaluate the relationship between gene expression (low/
high) and clinicopathological parameters, including age,
grade, stage, histological subtype and recurrence. The non-
parametric Mann–Whitney test was used to determine the
significance on the difference in the distribution of gene
expression in cancer, borderline and normal samples.
Kaplan-Meier and the log rank test were used for survival
analyses (both overall survival; from diagnosis to death of
any cause and disease-free survival; from diagnosis to
relapse). The SPSS 15.0 software was used to carry out the
statistical analyses. All P values reported were two-sided
and P < 0.05 was considered as statistically significant.
Results
Measurement of the mRNA levels of AMPK subunits
in ovarian tissues
Ovarian tissues, including tumor and normal tissues,
were used in the current study. The relative levels of the
six AMPK subunits including α1, α2, β1, β2, γ1, and γ2
in ovarian tissues were measured using real-time
Q-PCR. Expression of the AMPK-γ3 subunit was not
conducted because it is not expressed in ovarian tissues.
The mRNA levels of all AMPK subunits, except
AMPK-α1, were statistically significantly higher in ovar-
ian carcinomas than those of the normal controls
(Figure 1 & Table 1). Over-expressions of different
AMPK subunits independently occurred and were not
associated with one another.
Figure 1 Quantitative PCR analyses of the relative levels of six AMPK subunits in ovarian tissues. Except for AMPK-α1, the boxplots
indicate that statistically significant over-expressions of the other five AMPK subunits were detected in ovarian carcinomas compared with the
normal. Borderline tumors were excluded from the analysis because of the small sample size. The abbreviations are A1 = AMPK-α1; A2 = AMPK-α2;
B1 = AMPK-β1; B2 = AMPK-β2; G1 = AMPK-γ1; G2 = AMPK-γ2; Ca = Cancer; Normal N = 48; Borderline N = 5; Cancer N = 89.
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cellular locations of AMPK subunits in ovarian tissues
To further confirm the over-expressions of AMPK subu-
nits in ovarian carcinomas, IHC staining of each AMPKTable 1 The medians and ranges of the expression levels
of AMPK subunits in ovarian tissues
AMPK subunit Normal Borderline Cancer P value
α1 Median = 0.847 0.810 1.091 0.320
Range = 5.15 3.554 27.317
α2 Median = 0.766 1.525 1.791 <0.001
Range = 9.205 5.652 59.627
β1 Median = 0.873 2.72 3.189 <0.001
Range = 6.134 24.258 58.943
β2 Median = 0.132 0.311 0.283 0.001
Range = 0.53 4.14 7.83
γ1 Median = 0.568 0.706 1.693 <0.001
Range = 3.76 1.63 17.14
γ2 Median = 0.341 0.39 0.685 0.001
Range = 1.813 0.641 14.732subunit was carried out separately on an ovarian tissue
array slide.
IHC was successful using the antibodies against
AMPK-α1, -α2, -β1, and -β2. However, IHC using anti-
bodies against AMPK-γ1 and -γ2 subunits was not suc-
cessful, and the protein levels of the two γ subunits
cannot be determined. Consistent with Q-PCR results,
AMPK-α2, -β1, and -β2 subunits were over-expressed in
ovarian carcinomas compared with the normal controls
(Figure 2), whereas AMPK-α1 expression generally had
no significant difference between cancer samples and
normal controls.
Concerning the cellular locations of the AMPK subu-
nits, all four subunits were detected in the cytoplasm. In
addition, AMPK-α2 and -β1 were also detected in the
nucleus and cell membrane, respectively (Figure 2). The
active form of AMPK, the phospho-AMPK-α was only
detected in the cytoplasm (Figure 3).
Cellular locations of AMPK subunits in ovarian cancer cells
To confirm further the cellular locations of the AMPK
subunits detected in IHC, confocal microscopy was used
to localize the AMPK subunits in ovarian cancer cells
AMPK- 1 in benign tissue AMPK- 1 in tumor
AMPK- 2 in benign tissue AMPK- 2 in tumor
AMPK- 1 in benign tissue AMPK- 1 in tumor
AMPK- 2 in benign tissue AMPK- 2 in tumor
Figure 2 Immunohistochemical staining of AMPK-α1, -α2, -β1, and -β2 expressions in ovarian tissues. The over-expression of AMPK-α2
was observed in this representative tumor case. The expression of AMPK-α1 was detected in the cytoplasm only, whereas the expression of
AMPK-α2 was detected in both cytoplasm and nucleus (indicated by an arrow). N.B. For AMPK-α1, in this particular tumor sample, AMPK-α1
expression was higher than the normal. This clearly indicated that AMPK-α1 was only expressed in the cytoplasm. Over-expressions of AMPK-β1
and AMPK-β2 were also observed in the two representative tumor cases. Expression of AMPK-β2 was detected in the cytoplasm only, whereas
expression of AMPK-β1 was detected in both cytoplasm and cell membrane (indicated by an arrow).
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A2780CP cell (Figure 4). Expression of AMPK-α2 was
detected in both cytoplasm and nucleus. Expression of
AMPK-β1 was observed in the cytoplasm as well as in
the cellular membrane. Thus, the expressions of AMPK-
α2 and AMPK-β1 detected either by IHC or confocal mi-
croscopy match with each other. Although IHC was notsuccessful in detecting AMPK-γ2, expressions of AMPK-
γ2 were evenly detected in the cytoplasm, membrane,
and nucleus of the A2780CP cell (Figure 4). The cellular
locations of AMPK-β1 and -γ2 in another ovarian cancer
cell SKOV3 were shown in Additional file 1: Figure S1.
These results indicate that the expressions of AMPK
subunits are quite distinct from one another.
Phospho-AMPK-alpha in tumor 
Figure 3 Immunohistochemical staining of pAMPK-α expression
in ovarian tissue. The active form of AMPK, pAMPK-α, was only
detected in the cytoplasm.
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histological subtypes of ovarian carcinoma
After determining the expression levels of the various
AMPK subunits by Q-PCR, the relationships betweenA
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Figure 4 Localization of AMPK subunits in A2780CP cell. Enforced exp
A2780CP. The expression of AMPK-α2 was evenly detected in both cytopla
cytoplasm as well as in the cellular membrane. The expression of AMPK-γ2
A2780CP cell. A2780CP-V is a GFP vector control.the expression levels of the various AMPK subunits and
clinicopathological data were analyzed. The ovarian car-
cinoma samples were divided into two groups based on
the relative expression levels of the AMPK subunits, that
is, greater than or smaller than/equal to two-folds of the
mean of the relative expression levels of the normal sam-
ples. The two groups of samples were then correlated with
the clinicopathological parameters of the samples used in
the current study. Table 2 summarizes the results of all
correlations. The details of the correlation analyses are
shown in Additional file 2: Table S1 to Table S7.
The high expression of the AMPK-α2 subunit was
found to be associated with endometrioid carcinomas
(Additional file 2: Table S2). On the other hand, the high
expressions of the AMPK-β and -γ subunits were found to
be associated with mucinous (Additional file 2: Table S3
and Table S4) and serous carcinomas (Additional
file 2: Table S5 and Table S6), respectively. Clear cell car-
cinomas had no association with any of the high expres-
sions of the AMPK subunits (Additional file 2: Table S1 to
Table S6). Since the antibodies for detecting AMPK-γ sub-
units were not good enough for IHC, we can only present
the IHC staining quantifications of the AMPK-α and β
subunits. The results are shown in Additional file 2: TableFP Merge
ressions of AMPK-α2, -β1, and -γ2 tagged with GFP were carried out in
sm and nucleus. Expression of AMPK-β1 was observed in the
was evenly detected in the cytoplasm, membrane, and nucleus in
Table 2 Summary of association between high expression of AMPK subunits and clinical data
AMPK subunit Chromosomal location Cell type Grade Stage Recurrence
Alpha 1 5p13 Mucinous* NC NC NC
Alpha 2 1p32 Endometrioid NC NC Lower rate
Beta 1 12q24 Mucinous NC Early NC
Beta 2 1q21 Mucinous NC NC NC
Gamma 1 12q13 Serous NC NC NC
Gamma 2 7q36 Serous Low Late NC
*Although AMPK-α1 is not generally significantly over-expressed in ovarian cancer, high expression of the AMPK-α1 still has an association with mucinous carcinoma
(Additional file 2: Table S1). NC = No Correlation.
A
B
Figure 5 Patients’ survival analyses. Patients with high expression
of AMPK-α2 had (A) better overall survival and (B) disease free survival.
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the various histological subtypes in the tissue various
greatly, it is not easy to match the results between Q-PCR
and IHC staining. Nevertheless, the results determined by
Q-PCR and IHC staining match one another in the grade
and stage of diseases as described below.
Expressions of AMPK subunits in different stages of ovarian
carcinomas
The expressions of various AMPK subunits were also
correlated with the stages of the disease. High expres-
sions of AMPK-β1 (Additional file 2: Table S3) and
AMPK-γ2 (Additional file 2: Table S6) were found in the
early and late stages of the disease, respectively. The
expressions of other AMPK subunits had no correlation
with the stages of the disease. The correlation between
AMPK-β1 expression and the stage of the disease was
further confirmed by IHC results (Additional file 2:
Table S10).
Correlation between AMPK-γ2 and grades of ovarian
carcinomas
The high expression of AMPK-γ2 was associated with
low-grade tumors (Additional file 2: Table S6). However,
this result cannot be further confirmed because IHC
staining of AMPK-γ subunits was not successful. The
expressions of other AMPK subunits had no association
with the grades of tumors.
Correlation between AMPK-α2 and disease survival
Patients with high expressions of AMPK-α2 had less dis-
ease recurrence rate (Additional file 2: Table S2) and
better overall and disease-free survival rate (Figure 5).
This finding is consistent with the results described in
another report [13].
Discussion
In the present study, the detection of the over-
expressions of AMPK subunits in ovarian carcinomas
was described. The high expressions of the AMPK subu-
nits have significant correlations with one or more
clinicopathological parameters. Concerning AMPK-γsubunits, the antibodies from another source were also
used. However, they were still not good enough to reveal
the expression of AMPK-γ subunits at the protein level
by IHC. From Western blotting analysis, AMPK -γ1
and -γ2 were detectable in a number of human ovarian
surface epithelial cell lines and ovarian cancer cell lines
(data not shown). Thus, we excluded the possibility of
negative expression of AMPK -γ1 and -γ2. Nevertheless,
based on the good correlation between Q-PCR and IHC
results on AMPK-α and -β subunits, the expressions of
the AMPK-γ subunits measured by Q-PCR may also
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ovarian tissues. Certainly, further confirmation is needed
when antibodies against AMPK-γ subunits with the quality
for IHC analysis become available in the future.
AMPK is a heterotrimer containing the α, β, and γ
subunits, all of which are essential for kinase activity [2].
Thus, the expressions of the three different subunits
should be regulated closely to keep their levels in bal-
ance for the formation of the AMPK complex. However,
AMPK-α2, -β1, -β2, -γ1, and -γ2 were independently
over-expressed in ovarian carcinomas. AMPK subunits
are encoded by distinct genes located at different chromo-
somal regions (Table 2). This may explain their independ-
ent over-expressions during ovarian carcinogenesis.
Further, the association between the expressions of a par-
ticular AMPK subunit with a particular histological sub-
type of ovarian carcinoma further demonstrated that
AMPK subunits can express independently to one an-
other. Our data provide evidence on the complexity of
genetic alterations during the development of cancer.
In a previous study, AMPK-α1 was over-expressed in
about 50% of cases of cervical cancer [11] but without
association with any clinical parameters. In contrast,
although no statistically significant over-expression of
AMPK-α1 was found in ovarian cancers, the high
expression of AMPK-α1 was associated with the mucin-
ous type of ovarian carcinoma (Additional file 2: Table
S1). The expression of AMPK-α1 was predominantly
found in the nuclei of cervical cancer cells [11]. In con-
trast, in the present study, AMPK-α1 expression was
mainly found in the cytoplasm of ovarian cancer cells.
Based on the results of these two studies, the over-
expressions of different AMPK subunits in human can-
cers can be hypothesized to be tumor-type specific. Dif-
ferent cancers may have different expression statuses of
various AMPK subunits. Further investigation is needed
to delineate the expression status of AMPK subunits in
various human cancers and the clinical implications of
their expressions during cancer development.
Consistent with another report [13], ovarian cancer
patients with high expressions of AMPK-α2 with better
prognosis were also found in the present study. Tumors
with low expressions of AMPK-α2 may be more aggressive
in nature. This observation leads to another important
question on the potential functional roles of AMPK subu-
nits in ovarian cancer. In addition, the IHC results indi-
cated that AMPK-α2 and -β1 were also specifically
detected in the nucleus and cell membrane, respectively.
The active form of AMPK was only detected in the cyto-
plasm (Figure 3), so this result implied that AMPK-α2 and
-β1 subunits may have distinct functions other than just
being components of the heterotrimeric AMPK complex.
In an earlier study [14], under hypoxic condition,
AMPK-α2 expression was up-regulated and shuttled tothe nucleus to promote cell survival by enhancing the
hypoxia-induced VEGF expression in human glioblast-
oma cells. The potential function of AMPK-α subunits
was further demonstrated. In a yeast two-hybrid experi-
ment utilizing the HeLa cDNA library, the specific inter-
action between AMPK-α and p73α was shown. Both
AMPK-α1 and -α2 can repress the tumor suppressor
function of p73α and enhance the growth of H1299
(non-small cell lung carcinoma cell line) and U2OS
(human osteosarcoma cell line) cells without involving
the activity of AMPK [15]. In another study by Li et al.
[16], the forced expression of AMPK-β1 inhibits the
growth of H1299 and U2OS cells. This finding indicates
that different AMPK subunits have different func-
tional roles in controlling cell growth. Knowledge on
the functional roles of AMPK subunits in human can-
cers is still limited. In addition to expression status,
further investigation of the functions of AMPK subu-
nits is warranted. Functional studies may help in
understanding the roles of these subunits in ovarian
carcinogenesis.
Conclusions
In this study, aberrant expressions of AMPK subunits
were detected in ovarian carcinomas. More importantly,
the high expressions of individual AMPK subunits have
significant correlations with one or more clinicopatholo-
gical parameters. These results suggest that expressions
of AMPK subunits may play significant roles in the
development of ovarian cancer.
Additional files
Additional file 1: Figure S1. Localization of AMPK subunits in SKOV3
cell. Enforced expressions of AMPK-β1, and -γ2 tagged with GFP were
carried out in SKOV3 cell. The expression of AMPK-β1 was observed in
the cytoplasm as well as in the cellular membrane. The expression of
AMPK-γ2 was evenly detected in the cytoplasm, membrane and, nucleus
in SKOV3 cell. SKOV3-V is a GFP vector control.
Additional file 2: Table S1. AMPK-α1 expression and clinicopathologic
factors in ovarian cancer determined by Q-PCR. Table S2. AMPK-α2
expression and clinicopathologic factors in ovarian cancer determined by
Q-PCR. Table S3. AMPK-β1 expression and clinicopathologic factors in
ovarian cancer determined by Q-PCR. Table S4. AMPK-β2 expression and
clinicopathologic factors in ovarian cancer determined by Q-PCR. Table
S5. AMPK-γ1 expression and clinicopathologic factors in ovarian cancer
determined by Q-PCR. Table S6. AMPK-γ2 expression and
clinicopathologic factors in ovarian cancer determined by Q-PCR. Table
S7. Frequencies of high and low expressions of AMPK subunits in various
histological subtypes of ovarian cancer. Table S8. AMPK-α1 expression
and clinicopathologic factors in ovarian cancer determined by IHC
staining. Table S9. AMPK-α2 expression and clinicopathologic factors in
ovarian cancer determined by IHC staining. Table S10. AMPK-β1
expression and clinicopathologic factors in ovarian cancer determined by
IHC staining. Table S11. AMPK-β2 expression and clinicopathologic factors
in ovarian cancer determined by IHC staining.
Competing interests
The authors declare that they have no competing interests.
Li et al. BMC Cancer 2012, 12:357 Page 8 of 8
http://www.biomedcentral.com/1471-2407/12/357Authors’ contributions
CL and VWSL carried out most of the experiments and did the preparation
of the manuscript. PMC did the immunohistochemical staining. HYSN
provided the clinical samples and data and patient’s consent for the study.
DWC and HYSN helped to analyze all the data and critical comments on the
manuscript. All authors read and approved the manuscript to be submitted
for publication.
Acknowledgement
This study was supported by the Wong Check She Charitable Foundation.
Received: 14 September 2011 Accepted: 16 July 2012
Published: 16 August 2012
References
1. Hardie DG: AMP-activated/SNF1 protein kinases: conserved guardians of
cellular energy. Nat Rev Mol Cell Biol 2007, 8:774–785.
2. Steinberg GR, Kemp BE: AMPK in Health and Disease. Physiol Rev 2009,
89:1025–1078.
3. Shackelford DB, Shaw RJ: The LKB1–AMPK pathway: metabolism and
growth control in tumour suppression. Nat Rev Cancer 2009, 9:563–575.
4. Fogarty S, Hardie DG: Development of protein kinase activators: AMPK as
a target in metabolic disorders and cancer. Biochim Biophys Acta 2010,
1804:581–591.
5. Yu SY, Chan DW, Liu VW, Ngan HY: Inhibition of cervical cancer cell
growth through activation of upstream kinases of AMP-activated protein
kinase. Tumour Biol 2009, 30:80–85.
6. Gotlieb WH, Saumet J, Beauchamp MC, Gu J, Lau S, Pollak MN, Bruchim I: In
vitro metformin anti-neoplastic activity in epithelial ovarian cancer.
Gynecol Oncol 2008, 110:246–250.
7. Rattan R, Giri S, Hartmann LC, Shridhar V: Metformin attenuates ovarian
cancer cell growth in an AMP-kinase dispensable manner. J Cell Mol Med
2011, 15:166–178.
8. Yasmeen A, Beauchamp MC, Piura E, Segal E, Pollak M, Gotlieb WH: Induction
of apoptosis by metformin in epithelial ovarian cancer: Involvement of the
Bcl-2 family proteins. Gynecol Oncol 2011, 121:492–498.
9. Brenman JE: AMPK/LKB1 signaling in epithelial cell polarity and cell
division. Cell Cycle 2007, 6:2755–2759.
10. Schmittgen TD, Livak KJ: Analyzing real-time PCR data by the
comparative C(T) method. Nat Protoc 2008, 3:1101–1108.
11. Huang FY, Chiu PM, Tam KF, Kwok YK, Lau ET, Tang MH, Ng TY, Liu VW,
Cheung AN, Ngan HY: Semi-quantitative fluorescent PCR analysis
identifies PRKAA1 on chromosome 5 as a potential candidate cancer
gene of cervical cancer. Gynecol Oncol 2006, 103:219–225.
12. Wang Y, Chan DW, Liu VW, Chiu PM, Ngan HY: Differential functions of
growth factor receptor-bound protein 7 (GRB7) and its variant GRB7v in
ovarian carcinogenesis. Clin Cancer Res 2010, 16:2529–2539.
13. Hallstrom TC, Mori S, Nevins JR: An E2F1-dependent gene expression
program that determines the balance between proliferation and cell
death. Cancer Cell 2008, 13:11–22.
14. Neurath KM, Keough MP, Mikkelsen T, Claffey KP: AMP-dependent protein
kinase alpha 2 isoform promotes hypoxia-induced VEGF expression in
human glioblastoma. Glia 2006, 53:733–743.
15. Lee YG, Lee SW, Sin HS, Kim EJ, Um SJ: Kinase activity-independent
suppression of p73alpha by AMP-activated kinase alpha (AMPKalpha).
Oncogene 2009, 28:1040–1052.
16. Li J, Jiang P, Robinson M, Lawrence TS, Sun Y: AMPK-beta1 subunit is a
p53-independent stress responsive protein that inhibits tumor cell
growth upon forced expression. Carcinogenesis 2003, 24:827–834.
doi:10.1186/1471-2407-12-357
Cite this article as: Li et al.: Over-expressions of AMPK subunits in
ovarian carcinomas with significant clinical implications. BMC Cancer
2012 12:357.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
